Ongentys Now Available as Add-On Treatment for Parkinson Disease
Ongentys is an oral, selective and reversible inhibitor of catechol-O-methyltransferase.
Parkinson Disease
New Drug Application for Apomorphine Infusion Pump Submitted for Review
The NDA for SPN-830 is supported by data from an extensive development program that includes the phase 3 TOLEDO study and a supportive open-label study.
Pimavanserin Effective for Depression in Parkinson Disease, Major Depressive Disorder
Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.
Fatigue, Daytime Sleepiness, and Apathy Predict Fatigue Severity in PD
In early Parkinson Disease, fatigue, excessive daytime sleepiness, and emotional apathy are predictive of increasing fatigue severity.
Healthy Diet Inversely Linked to Prodromal Parkinson Disease Features
Increased adherence to alternate Mediterranean and Alternative Healthy Eating Index dietary patterns is inversely associated with prodromal features of Parkinson disease.
Microstructural Imaging May Capture Early Parkinson Disease Progression
Researchers sought to determine the relationship between neuroimaging markers and other clinical characteristics with mild parkinsonian signs in older adults.
Reduced Circadian Rhythmicity Tied to Increase in Parkinson Disease
Results from a sleep study indicate a reduced circadian rhythmicity is associated with an increased risk for incident Parkinson disease.
Fractures More Common During Prodromal Period of Parkinson Disease
Researchers examined the association between fractures and Parkinson disease during the prodromal period.
Therapeutic Options for Peripheral Neuropathy in Parkinson Disease
The etiology and management of peripheral neuropathy in Parkinson disease is discussed.
Extended-Release Amantadine Under Review for Off Episodes in Parkinson Disease
The FDA has accepted for review the supplemental New Drug Application for Gocovri® for the treatment of off episodes in Parkinson disease patients receiving levodopa-based therapy.
-
Loading...
-
Loading...
Next post in Movement Disorders
